[1] Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial[J]. Lancet Respir Med, 2020, 8(3): 267-276. [2] Lewis S R, Pritchard M W, Thomas C M, et al. Pharmacological agents for adults with acute respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2019, 7(7):CD004477. [3] Mungan İ, Bektaş Ş,Altınkaya Çavuş M, et al. The predictive power of SAPS-3 and SOFA scores and their relations with patient outcomes in the surgical intensive care unit[J]. Turk J Surg, 2019, 35(2):124-130. [4] 郭晓娟,田国祥,闫小妮,等. eICU合作研究数据库申请及数据提取流程[J]. 中国循证心血管医学杂志, 2019, 11(1): 6-9. [5] Pollard T J, Johnson A E W, Raffa J D, et al. The eICU Collaborative Research Database, a freely available multi-center database for critical care research[J]. Sci Data, 2018, 5:180178. [6] Keegan M T, Gajic O, Afessa B. Comparison of APACHE Ⅲ, APACHE Ⅳ, SAPS 3, and MPMOⅢ and influence of resuscitation status on model performance[J]. Chest, 2012, 142(4): 851-858. [7] Nassar A P, Malbouisson L M, Moreno R. Evaluation of Simplified Acute Physiology Score 3 performance: a systematic review of external validation studies [J]. Crit Care, 2014, 18(3):R117. [8] 杜斌. 急性呼吸窘迫综合征的柏林定义:究竟改变了什么? [J]. 首都医科大学学报, 2013, 34(2): 201-203. [9] Matera M G, Rogliani P, Bianco A, et al. Pharmacological management of adult patients with acute respiratory distress syndrome[J]. Expert Opin Pharmacother, 2020, 21(17):2169-2183. [10] Fan E, Brodie D, Slutsky A S. Acute respiratory distress syndrome: advances in diagnosis and treatment [J]. JAMA, 2018, 319(7):698-710. [11] Ye Z, Wang Y, Colunga-Lozano L E, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis[J]. CMAJ, 2020, 192(27):E756-E767. [12] Zhan Y, Shang J, Gu Y, et al. Efficacy of corticosteroid in patients with COVID-19: a multi-center retrospective study and meta-analysis[J]. J Med Virol, 2021, 93(7): 4292-4302. [13] RECOVERY Collaborative Group, Horby P, Lim W S, et al. Dexamethasone in Hospitalized Patients with Covid-19[J]. N Engl J Med, 2021, 384(8):693-704. [14] Menezes R C, Ferreira I B B, Carmo T A, et al. Are prognostic tools losing accuracy? Development and performance of a novel age-calibrated severity scoring system for critically ill patients[J]. PLoS One, 2020, 15(11):e0240793. [15] Shadnia S, Zamani N, Hassanian-Moghaddam H, et al. Prognostic value of cortisol and thyroid function tests in poisoned patients admitted to toxicology ICU[J]. World J Emerg Med, 2018, 9(1):51-55. [16] Meduri G U, Rochwerg B. Point: should corticosteroids be routine treatment in early ARDS? Yes[J]. Chest, 2021, 159(1):25-29. [17] 董红建,谭捷.糖皮质激素联合参芪扶正注射液辅治重症社区获得性肺炎致ARDS患者效果观察及对血清炎性因子、血气指标影响[J].临床误诊误治,2019,32(11):25-29. [18] Nicolaides N C, Kyratzi E, Lamprokostopoulou A, et al. Stress, the stress system and the role of glucocorticoids[J]. Neuroimmunomodulation, 2015, 22(1-2): 6-19. [19] Mokra D, Mikolka P, Kosutova P, et al. Corticosteroids in acute lung injury: the dilemma continues[J]. Int J Mol Sci, 2019, 20(19):4765. [20] Villar J, Confalonieri M, Pastores S M, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019[J]. Crit Care Explor, 2020, 2(4): e0111. [21] Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial[J]. JAMA, 2015, 313(7): 677-686. [22] WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne J A C, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis[J]. JAMA, 2020, 324(13): 1330-1341. [23] Annane D, Pastores S M, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017[J]. Intensive Care Med, 2017, 43(12): 1751-1763. [24] Oh D K. Corticosteroids in acute respiratory distress syndrome: outcomes obscured by mortality[J]. Korean J Intern Med, 2021, 36(1):65-66. |